What is he best known for?
The fields of study he is best known for:
Gurdyal S. Besra spends much of his time researching Biochemistry, Mycobacterium tuberculosis, Microbiology, Natural killer T cell and Antigen.
His Biochemistry study combines topics from a wide range of disciplines, such as Mycobacterium and Mycobacterium smegmatis.
His research investigates the link between Mycobacterium tuberculosis and topics such as Isoniazid that cross with problems in Drug resistance.
In Microbiology, he works on issues like Lipoarabinomannan, which are connected to Mannosyltransferase and Mannose.
His research integrates issues of Cell activation and Cell biology in his study of Natural killer T cell.
His Antigen study also includes
- T cell, which have a strong connection to Endosome,
- Antigen presentation which connect with CD1.
His most cited work include:
- Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum (630 citations)
- Role of the Major Antigen of Mycobacterium tuberculosis in Cell Wall Biogenesis (595 citations)
- Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis (483 citations)
What are the main themes of his work throughout his whole career to date?
Biochemistry, Mycobacterium tuberculosis, Microbiology, CD1D and Natural killer T cell are his primary areas of study.
His Biochemistry study incorporates themes from Stereochemistry and Mycobacterium.
Gurdyal S. Besra studied Mycobacterium tuberculosis and Mutant that intersect with Corynebacterium glutamicum.
In his study, Mannose and Mannosyltransferase is strongly linked to Lipomannan, which falls under the umbrella field of Microbiology.
Gurdyal S. Besra combines subjects such as Cell activation and Cell with his study of CD1D.
While the research belongs to areas of Natural killer T cell, Gurdyal S. Besra spends his time largely on the problem of Cell biology, intersecting his research to questions surrounding Antigen presentation.
He most often published in these fields:
- Biochemistry (43.94%)
- Mycobacterium tuberculosis (30.10%)
- Microbiology (20.24%)
What were the highlights of his more recent work (between 2014-2021)?
- Mycobacterium tuberculosis (30.10%)
- Biochemistry (43.94%)
- CD1D (17.99%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Mycobacterium tuberculosis, Biochemistry, CD1D, Tuberculosis and Cell biology.
His biological study spans a wide range of topics, including Peptidoglycan, Cell wall, Microbiology and Drug discovery.
Much of his study explores Biochemistry relationship to In vivo.
He studied CD1D and Antigen presentation that intersect with MHC class I.
His Cell biology study integrates concerns from other disciplines, such as Inflammation, Cell, Cell growth and Antigen-presenting cell.
His Antigen research is multidisciplinary, relying on both Glycolipid and T-cell receptor.
Between 2014 and 2021, his most popular works were:
- Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of Treg cells and macrophages in adipose tissue (224 citations)
- Assembly of the Mycobacterial Cell Wall. (164 citations)
- Inflammation-induced formation of fat-associated lymphoid clusters (96 citations)
In his most recent research, the most cited papers focused on:
His main research concerns Cell biology, Immunology, CD1D, Biochemistry and Mycobacterium tuberculosis.
His Cell biology research includes themes of Inflammation and Cell, Cell type.
The study of Natural killer T cell and Immune system are components of his CD1D research.
His work in Biochemistry is not limited to one particular discipline; it also encompasses Bacteria.
The Mycobacterium tuberculosis study combines topics in areas such as Computational biology and Microbiology.
His Microbiology research integrates issues from Cell envelope, Cell wall, Virulence and Tuberculosis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
